By Lucy Parkinson, Director of Research, LSN
Major pharma firms are increasingly looking externally for innovative technologies, and strategic venture investments are a key part of many firms’ strategies for participating in the early stage ecosystem. Firms may use subsidiary corporate venture funds, or may have an internal unit for making strategic investments in startups that are relevant to their pipeline.
At RESI San Francisco on Tuesday January 10th, the Corporate VC panel will bring together investors from 5 different corporate VCs to cover how they invest on behalf of their parent pharma companies.
The panelists are:
- Tracy Saxton, Investment Director, Roche Venture Fund
- Ron Newbold, Vice President, External R&D Innovation, Americas and Europe, Pfizer Inc.
- Hakan Goker, Investment Director, Merck Ventures
- Laurent Audoly, Managing Director, Pierre Fabre Fund for Innovation
- Jason P. Hafler, Senior Director of Investments, Sanofi-Genzyme BioVentures
In this panel, corporate VC investors will discuss the types of companies they’re interested in investing in, and how they structure these opportunities to achieve their strategic aims. Panelists will provide advice on how entrepreneurs can engage with a corporate investor, and how they bridge the gap between early stage startups and major pharmaceutical corporations.
If you’d like to be there in person, you can register for RESI now.
Next Phase Newsletter 
Leave a Reply